Get started
Author

Daniela Bellarosa

Observed names: Bellarosa, Daniela, D BELLAROSA, D Bellarosa, D. BELLAROSA, D. Bellarosa, DANIELA BELLAROSA
OpenAlex ID: A5019249845
Apoptotic Events in a Human Ovarian Cancer Cell Line Exposed to Anthracyclines
2001 · Daniela Bellarosa, Alessandra Ciucci, et al. · Journal of Pharmacology and Experimental Therapeutics · 55
Inhibition of telomerase activity by a distamycin derivative: effects on cell proliferation and induction of apoptosis in human cancer cells
2002 · N Zaffaroni, S Lualdi, et al. · European Journal of Cancer · 38
In vitro Selection of Human Immunodeficiency Virus Type 1 Resistant to Ro 31-8959 Proteinase Inhibitor
1993 · F. Dianzani, G. Antonelli, et al. · Antiviral chemistry & chemotherapy · 29
SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line
2012 · DANIELA BELLAROSA, ALESSANDRO BRESSAN, et al. · International Journal of Oncology · 28
PDF
New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase
1996 · D BELLAROSA, G ANTONELLI, et al. · Antiviral Research · 26
MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
2019 · Giuseppe Merlino, Alessio Fiascarelli, et al. · Molecular Cancer Therapeutics · 24
PDF
Synthesis and anti HIV-1 activity of new thiadiazepindioxides
1995 · Danilo Giannotti, Giovanni Viti, et al. · Bioorganic & Medicinal Chemistry Letters · 18
CD157: From Myeloid Cell Differentiation Marker to Therapeutic Target in Acute Myeloid Leukemia
2019 · Yuliya Yakymiv, Stefania Augeri, et al. · Cells · 17
PDF
Sabarubicin- (MEN 10755) and paclitaxel show different kinetics in nuclear factor-kappaB (NF-kB) activation: effect of parthenolide on their cytotoxicity.
2005 · Daniela Bellarosa, Monica Binaschi, et al. · PubMed · 16
A comparative study of cellular and molecular pharmacology of doxorubicin and MEN 10755, a disaccharide analogue11Abbreviations: DOX, doxorubicin; DNA-SSB, single-strand breaks; and DNA-DSB, double-strand breaks.
2001 · Mario Bigioni, Carmela Salvatore, et al. · Biochemical Pharmacology · 16
The Synergistic Interaction of Interferon Types I and II Leads to Marked Reduction in Severe Acute Respiratory Syndrome-Associated Coronavirus Replication and Increase in the Expression of mRNAs for Interferon-Induced Proteins
2006 · Carolina Scagnolari, Simona Trombetti, et al. · Intervirology · 14
Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
2023 · Alessio Fiascarelli, Giuseppe Merlino, et al. · Breast Cancer Research and Treatment · 10
PDF
Antitumor activity of delimotecan against human metastatic melanoma: Pharmacokinetics and molecular determinants
2009 · Mario Bigioni, Massimo Parlani, et al. · International Journal of Cancer · 10
PDF
Drug Combination of AZT and ddl: Synergism of Action and Prevention of Appearance of AZT-Resistance
1994 · G. Antonelli, F. Dianzani, et al. · Antiviral chemistry & chemotherapy · 10
Human and murine macrophages mediate activation of MEN 4901/T-0128: a new promising camptothecin analogue–polysaccharide conjugate
2006 · Monica Binaschi, Massimo Parlani, et al. · Anti-Cancer Drugs · 9
The Dual PIM / FLT3 Inhibitor MEN1703 Combines Synergistically With Gilteritinib in FLT3 ‐ ITD ‐Mutant Acute Myeloid Leukaemia
2024 · Sonia Zicari, Giuseppe Merlino, et al. · Journal of Cellular and Molecular Medicine · 5
PDF
MEN1112/OBT357, an Anti Bst1/CD157 Humanized Antibody Inducing Acute Myelogenous Leukemia (AML) Blast Depletion in an Autologous Ex Vivo Assay: A Potential New Targeted Therapy for AML
2015 · Adriano Venditti, Francesco Buccisano, et al. · Blood · 4
Tagraxofusp Shows Promising Anti-Tumoral Efficacy in Preclinical in Vitro Models of Myelofibrosis, Both As a Single Agent and in Combination with Janus Kinase Inhibitors
2023 · Maria Luisa Iannitto, Diego Bisignano, et al. · Blood · 3
SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial
2021 · Alessandro Paoli, Daniela Bellarosa, et al. · Blood · 3
Abstract C144: MEN1703/SEL24, a potent PIM inhibitor, demonstrates promising anti-tumour activity in activated B cell like diffuse large B cell lymphoma, mantle cell lymphoma and marginal zone lymphoma cells
2023 · Afua A. Mensah, Alessandro Ghiringhelli, et al. · Molecular Cancer Therapeutics · 2
First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia
2019 · Scott R. Solomon, Aziz Nazha, et al. · Blood · 2
Reduced Formation of Advanced Glycation End Products Induced by D-Lysine: Preliminary in vitro Observations
2015 · Maurizio Sensi, Flavia Pricci, et al. · Frontiers in diabetes · 2
An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
2025 · Herve Ghesquieres, Malgorzata Krawczyk-Kulis, et al. · Blood · 1
PDF
PIM Kinases Regulate Super-Enhancer-Dependent Gene Expression in Diffuse Large B-Cell Lymphoma
2022 · Sonia Debek, Dorota Komar, et al. · Blood · 1
Super-Enhancer-Driven PIM Kinase Upregulation in Multiple Myeloma Maintains the Plasma Cell-Specific Oncogenic and Microenvironmental Circuits, and Can be Efficiently Targeted By the Pan-PIM Inhibitor MEN1703
2022 · Filip Garbicz, Sonia Debek, et al. · Blood · 1
Works count: 60
Citation count: 346
H-index: 11
I10-index: 14
Year
Topic
Type